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Abstract
There is an increasing demand for personalization of disease screening based on assessment of 
patient risk and other characteristics. For example, in breast cancer screening, advanced imaging 
technologies have made it possible to move away from “one-size-fits-all” screening guidelines to 
targeted risk-based screening for those who are in need. Since diagnostic performance of various 
imaging modalities may vary across subjects, applying the most accurate modality to the patients 
who would benefit the most requires personalized strategy. To address these needs, we propose 
novel machine learning methods to estimate personalized diagnostic rules for medical screening or 
diagnosis by maximizing a weighted combination of sensitivity and specificity across subgroups 
of subjects. We first develop methods that can be applied when competing modalities or screening 
strategies are observed on the same subject (paired design). Next, we present methods for studies 
where not all subjects receive both modalities (unpaired design). We study theoretical properties 
including consistency and risk bound of the personalized diagnostic rules, and conduct simulation 
studies to examine performance of the proposed methods. Lastly, we analyze data collected from a 
brain imaging study of Parkinson’s disease using positron emission tomography (PET) and 
diffusion tensor imaging (DTI) with paired and unpaired designs. Our results show that in some 
cases a personalized modality assignment is estimated to improve empirical AUC compared to a 
“one-size-fits-all” assignment strategy.
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1. Introduction
Breast cancer screening is one of the most common forms of cancer screening in the United 
States, where approximately 39 million screening examinations are performed each year [1]. 
Recently, there is an increasing demand for personalization of breast cancer screening based 
on assessment of patient risk, consideration of benefit and harm, and patient preferences [2]. 
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Although mammography remains the standard screening modality, new imaging 
technologies such as breast magnetic resonance imaging (MRI) may be more sensitive for 
some women with smaller lesion size and/or with denser breasts [3]. Similarly, recent 
research in prostate cancer has led the US Preventive Services Task Force to recommend 
prostate-specific antigen (PSA) screening in high risk population instead of the general 
population [4]. To formally study personalized screening strategies, initiatives such as the 
Population-based Research Optimizing Screening through Personalized Regimens 
(PROSPR) examine how to improve screening process by tailoring based on risk, imaging 
modalities, and preferences [5].
Besides the potential of personalization in cancer screening, there is also a demand for 
personalized screening in other medical fields such as mental disorders and neurological 
disorders. For example, with advances in neurobiology, the current National Institute of 
Mental Health (NIMH) Strategic Plan calls for the development of new ways of classifying 
psychopathology and mental disorders based on dimensions of observable behavior and 
biological measures [6, 7]. Brain imaging biomarkers provide an important source of 
information in addition to clinical symptoms to assist assessments of of mental disorders, 
although the science of using neuroimaging techniques to diagnose psychiatric conditions is 
in an early stage [6, 8]. For neurological disorders, some imaging studies have demonstrated 
group differences between patients and matched controls [9, 10]. Given that patient 
heterogeneity is commonly observed, it is conceivable that some imaging biomarkers may 
be more sensitive in certain subgroups of patients at different stage of disease progression. 
However, little work has been done to make personalized selection of imaging modalities, 
which could potentially improve diagnostic accuracy.
Parametric or semiparametric statistical methods have been developed in the literature to 
examine heterogeneity in the performance of medical tests and to combine tests to make 
diagnosis. For example, there are three approaches to compare various tests [11]: empirical 
methods, distribution modeling methods and distribution-free parametric methods [12, 13]. 
It is rare that a single biomarker can achieve adequate diagnostic accuracy, and there is a 
need to create composite measures by combining potentially large number of markers. These 
methods encounter challenges when the number of biomarkers increases. Some other 
relevant work aiming at identifying optimal combination of diagnostic markers include 
maximum-likelihood estimators based on generalized linear models or nonparametric 
models [14, 15]. However, their focus is on improving the overall performance of the 
combined test applied to the entire sample under a uniform strategy that administers the 
same test to all individuals.
An approach to achieve crude personalization when administering a diagnostic test is to 
compare the area under the receiver operating characteristic (ROC) curve for various testing 
modalities across subgroups. However, it is often unknown how to define subgroups, and 
thus the number of subgroups to be examined in an exploratory analysis increases 
exponentially. As a result, such an approach is subject to penalization by multiple 
comparisons, and thus cannot accommodate high-dimensional imaging measures or other 
biomarkers. Several recent work proposed machine learning methods to estimate 
personalized treatment regimens from data collected in multi-stage clinical trials [16, 17]. 
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The advantages of machine learning methods include minimal assumptions on the 
underlying data structure distribution and computational feasibility to handle high-
dimensional feature variables with moderate sample size. However, there has been little 
discussion on machine learning methods for studying personalized medical diagnosis and 
screening, despite the clear clinical needs.
The goal of this paper is to develop a data-driven machine learning method to determine the 
best diagnostic rule to assist personalized recommendation for screening and diagnostic 
practices. We propose to estimate the optimal screening rule depending on subject-specific 
characteristics to maximize a weighted combination of sensitivity and specificity. We show 
that identifying the optimal diagnostic rule is equivalent to a weighted classification 
problem. The estimated diagnostic rule automatically chooses between two competing 
modalities for each subject to maximize the performance and is guaranteed to perform at 
least as good as assigning the same modality to all subjects (one-size-fits-all rule). Paired 
and unpaired designs are considered: in a paired design, both competing modalities are 
administered to all subjects; by contrast, each subject receive only one modality in an 
unpaired design. The method can easily handle high-dimensional feature variables and 
incorporate flexible non-linearity and correlation among variables. Theoretical properties 
including consistency and risk bound are shown. Simulation studies demonstrate that the 
proposed method can improve the empirical area under the receiver operating curve (AUC). 
Lastly, we analyze data collected from a brain imaging study of Parkinson’s disease (PD) 
using Fludeoxyglucose Positron Emission Tomography (FDG-PET) and Diffusion Tensor 
Imaging - Structural Magnetic Resonance Imaging (DTI-MRI) under paired and unpaired 
designs. We show that a personalized modality assignment rule can improve the empirical 
AUC compared to a “one-size-fits-all” strategy and gain clinical insights.
2. Methods
2.1. Personalized diagnostic rules and performance measure
Consider a dichotomous disease outcome (D = 1: diseased and D = 0: non-diseased) and two 
diagnostic modalities or screening procedures (A versus B). Let X denote a vector of 
subject-specific characteristics including a subject’s risk factors or prognostic biomarkers. 
Our goal is to derive a decision rule to recommend one diagnostic modality depending on X 
such that for patients with feature variables X, sensitivity of the recommended modality is 
not lower than the alternative modality; while for healthy control subjects with the same 
feature variables X, specificity of the recommended modality is also not lower than the 
competing modality.
Diagnostic tests are often ordinal or dimensional measures. For example, in cancer screening 
studies, radiologists assess an image obtained from certain imaging modality and assign a 
diagnostic score to describe the likelihood of a subject having a benign or malignant test 
result. For breast cancer screening, the malignancy likelihood score, BI-RADS [18], is 
obtained from breast imaging studies where a radiologist rates a mammogram or other 
image into a BI-RADS score ranging from 0 to 6 (0: Incomplete, 1: Negative, 2: Benign 
finding, 3: Probably benign, 4: Suspicious abnormality, biopsy recommended, 5: Highly 
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suggestive of malignancy, biopsy recommended, 6: Known biopsy, proven malignancy). For 
neuropsychiatric disorders, biomarkres are explored to assist disease diagnosis [19, 7].
Denote YA as the diagnostic score rated using modality A and YB rated using modality B. 
Assume that YA and YB are rated on a common scale and a higher score is associated with 
greater likelihood of being diseased (or malignant). In a paired design, both diagnostic 
scores YA and YB are observed for each subject. Let (X) denote a screening rule 
determining the choice of modality A or B depending on the subject-specific characteristics, 
X, where (X) = 1 indicates choosing modality A and (X) = −1 indicates choosing 
modality B. That is, (·) maps X to {1, −1}. Note that a more sensitive modality will lead to 
a higher screening score for diseased subjects and a more specific modality will lead to a 
lower screening score for non-diseased subjects. Thus for diseased subjects, if YA > YB we 
expect an effective rule to assign (X) = 1 for high sensitivity; and if YA < YB, we expect 
(X) = −1. Equivalently, a desirable should yield a large value of
to achieve high sensitivity. Similarly, for non-diseased subjects, a desirable will yield a 
large value of
to achieve high specificity. To consider both sensitivity and specificity when estimating , 
introduce ω0 as a pre-specified weight in [0, 1] to balance the above two objectives with a 
default of ω0 = 0.5 if none is preferred. The goal for finding an optimal personalized 
diagnostic rule is then to solve an optimization problem:
(1)
One potential limitation of this objective function is that the derived rule does not 
differentiate between subjects with YA much larger than YB from subjects with only slightly 
greater YA compared to YB. A solution is to incorporate the difference between diagnostic 
scores under two modalities into the classification rule in (1). Specifically, define Z = |YA − 
YB| and we aim to solve the following objective function
(2)
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Since I(−1 ≠ (X)) = 1 − I(1 ≠ (X)), criterion (1) and (2) can be unified as
(3)
where W = ωD + (1 − ω)(1 − D) for (1) and W = [ωD + (1 − ω)(1 − D)]Z for (2). Here, ω = 
(ω0/p)/[ω0/p + (1 − ω0)/(1 − p)], where p is the disease prevalence. The decision rule that 
minimizes (3) is referred as the optimal personalized diagnostic rule, which we denote as 
*. In the following sections, we will propose methods to estimate * under paired and 
unpaired design.
2.2. Estimation under a paired design
When diagnostic tests do not interfere with each other and when feasible, paired design [11] 
where each subject is administered with both tests is used. Paired design minimizes between 
subjects variation in the estimation and eliminates the possibility of confounding. Therefore 
it provides more efficient assessment and valid comparison of the performance of each test. 
Specifically, in a paired diagnostic study, patients and controls are recruited and each subject 
receives two diagnostic modalities (or diagnostic tests), Ai and Bi. Radiologists blinded to 
the disease status give rating scores (e.g. BIRADS scores), YAi and YBi, respectively, to 
assess the likelihood of a disease (or malignancy). An empirical version of the minimization 
problem (3) based on n samples becomes
(4)
where Wi = ωDi + (1 − ω)(1 − Di) for (1), Wi = [ωDi + (1 − ω)(1 − Di)]Zi for (2), and Zi = |
YAi − YBi|.
Direct minimization of (4) is a difficult problem due to the discontinuity of the indicator 
function. However, the objective function in (4) is in fact the empirical weighted 
misclassification error rate in a classification problem treating Vi as class labels, Xi as 
feature variables, and each subject being weighted by Wi. Many machine learning 
techniques can be applied to find the optimal rule *. Particularly, we choose large margin 
classifiers due to their successful applications in many fields. Let f(x) be a diagnostic 
decision function associated with the classification rule , i.e., (x) = sign(f(x)), and define 
ℒ(υ f) as a large margin-based loss function, for example, hinge loss ℒ(υ f) = (1 − υ f)+ 
that is associated with Support Vector Machine (SVM) classifier [20, 21]. We propose to 
estimate the unknown decision function f via the minimization problem:
(5)
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where λn is a pre-specified tuning parameter, ℋ is a normed space to which f belongs, and ||
f||ℋ is the norm or the semi-norm defined in ℋ. Examples of ℋ include a linear space 
consisting of α + βT x and ||f||ℋ is the Euclidean norm of β, or a reproducing kernel Hilbert 
space (RKHS) [22, 23] based on some kernel function K(·, ·), and ||f||ℋ is the norm defined 
in this RKHS.
The optimization problem in (5) can be carried out via its dual problem. Following the KKT 
condition [24], one can easily show that its dual problem is
(6)
subject to constraints 0 ≤ αi ≤ Cn Wi, i = 1, …, n and , where Cn is the tuning 
parameter and Cn = 1/λn ([21], page 426). Here,< Xi, Xj > is the inner product defined in the 
space ℋ: if ℋ consists of linear function, then ; if ℋ is the RKHS 
embedded with kernel function K(·, ·), then < Xi, Xj >= K(Xi, Xj). For the latter, the most 
commonly used kernel function is the Gaussian kernel where 
and 1/σn is the bandwidth tuned using data. Here, we use the notation from [25] and σn is 
the reciprocal of the tuning parameter in traditional Gaussian kernel function. Because the 
optimization (6) only involves the inner product of Xi and Xj, the computational cost is 
related to the sample size n instead of the dimensionality of X. Thus, the high-
dimensionality of X does not cause computational difficulties in the kernel-based method 
once the distance is defined. Computationally, (6) can be solved by quadratic programming 
algorithms, and the tuning parameter Cn is selected using cross-validation across a grid 2−15, 
2−14, …, 214, 215.
When there are multiple radiologists providing rating scores for each modality, a simple 
method to incorporate results from multiple readers is to consider the average performance 
over the readers. That is, we solve the following problem to derive the personalized 
diagnostic rule:
where N is the number of readers and Wik and Vik are the corresponding weights and class 
labels defined for each subject i and reader k.
2.3. Estimation under an unpaired design
In many other diagnostic studies, subjects may not undergo multiple modalities due to 
interference, tests having significant risk, high cost, or simply non-feasible [11]. In these 
cases, an unpaired design, where one group of subjects receive diagnostic modality A and 
the other matched group of subjects receive diagnostic modality B, is used. Under an 
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unpaired design, directly comparing the diagnostic performance of A and B on the same 
subject is no longer feasible. Since subjects may receive only one of the two modalities, we 
introduce random variable M to denote the modality that the subject actually receives, where 
M = 1 indicates receiving A and M = −1 indicates receiving B. Let Y be the observed rating 
score which is YA if M = 1 and YB if M = −1. Since in an unpaired design each subject has 
only one outcome (YA or YB) observed, the minimization in (3) cannot be directly 
implemented using the observed data. To estimate the optimal personalized diagnostic rules 
using the unpaired data, we require missing at random (MAR) condition, (C.1): YA, YB and 
M are independent given X and D. The implication of (C.1) is that a subject’s modality 
assignment M in a diagnostic study is conditionally independent of their missing rating score 
given their observed feature variables X, disease status, and observed rating score. This 
condition also assumes that the dependence among patient’s observed and unobserved rating 
scores YA and YB must be fully explained by X and D. The MAR assumption (C.1) is 
necessary when borrowing other similar subjects’ diagnostic scores to infer a particular 
subject’s missing rating score on modality A or B.
To estimate (3), we use similar pairs of subjects where one receives modality A but the other 
receives B to approximate the terms in (3). Select a diseased subject (D = 1) who is tested by 
modality A and has feature variables X and rating score YA. Select another independent 
diseased subject (D̃ = 1) who is tested by modality B and has feature variables X̃ and rating 
score ỸB. If X and X̃ are close, under condition (C.1) we expect a desirable decision rule 
should assign the first subject to A if rating scores YA ≥ ỸB, and to B if rating scores YA < 
ỸB. Similarly, for a pair of non-diseased subjects, a desirable decision rule will choose the 
modality with rating scores YA ≤ ỸB. The similarity between two subjects is characterized 
using kernel distance kan (||X − X
̃||) where kan (·) is a kernel function with bandwidth an. In 
our simulation studies and real data analysis, an is chosen so that the pairs of samples with 
distance less than an is fixed to be a non-small portion of pairs (for example, 15% to 30%). 
Cross-validation can also be used to choose an with additional computational cost. 
Furthermore, since subjects may receive A or B with different probability since the modality 
is not randomized, we adjust for this propensity by inverse probability weighting, where we 
denote π(X, D) as the probability of M = 1 (receiving modality A) given X and D. 
Subsequently, for pairs of diseased subjects, a desirable decision rule (·) will yield a large 
value of
Similarly, for non-diseased pairs a desirable rule will lead to a large value of
As in a paired design, introducing ω0 as a weight for balancing sensitivity and specificity, 
we aim to maximize a weighted summation of the above two terms. Furthermore, to 
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incorporate the difference of the observed scores, we can include the magnitude of |YA − ỸB| 
in the above expectation and define weights ω as in the paired design.
To summarize, we maximize
(7)
where O = (YA, X, D), Õ = (ỸB, X̃, D̃), O and Õ are independent. Note here
and Q(O, Õ) = ωD + (1 − ω)(1 − D) if one does not weight by the difference on observed 
scores, while Q(O, Õ) = |YA − ỸB|{ωD + (1 − ω)(1 − D)} if one does. To see how (7) 
approximates (3), we note
where the last step uses the MAR assumption in (C.1). Moreover, when an converges to zero, 
the last term approximates the following quantity up to some constant
which is equivalent to
This follows by the conditional independence of YA and YB given (X, D) and the fact that 
ỸB is an independent copy of YB. Note that Q((YA, X, D), (YB, X, D)) = ωD + (1 − ω)(1 − 
D), if one does not weight by |YA − YB|; and it is Q((YA, X, D), (YB, X, D)) = |YA − YB| 
{ωD + (1 − ω)(1 − D)}, if one does. By the definition of W in Section 2.1, the maximization 
becomes
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which is exactly the same optimization problem as in (3). This justifies using (7) to find the 
optimal diagnostic rule.
Using data collected in an unpaired study, we can maximize the empirical version of (7), 
which is given as
where Vij = (2Di − 1)(2I(Mi = 1) − 1)sign(Yi − Yj), and p̂(M, X, D) is an estimator of p(M, 
X, D) by regressing M on (X, D). These propensity scores are obtained by logistic regression 
or other machine learning approaches. Again, due to the difficulty of optimization involving 
an indicator function (zero-one loss), one can replace it by a large-margin based loss 
function ℒ(·) as:
(8)
Similar to the paired design case, weighted support vector machine can be used to find the 
best rule *(x) when ℒ(·) is the hinge loss.
3. Theoretical Properties
In this section, we provide theoretical justification of the proposed optimal rule. We denote 
the expression (3), E[WI(V ≠ (X))], as ℛ(f) when (X) = sign(f(X)). Since
it is easy to see that the Bayes decision rule is given by
We further define Rℒ(f) = E[Wℒ(V f(X))] for a large margin loss ℒ(·). Then it is clear that 
our estimated rule minimizes the empirical version of Rℒ(f) for the paired design and 
minimize an approximated empirical version of Rℒ(f) in the unpaired design. Therefore, it is 
natural to ask whether the minimizer of Rℒ(f) also minimizes ℛ(f). Our first theorem gives 
this Fisher consistency and compares the approximation error due to using Rℒ(f).
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If f̃ minimizes Rℒ(f), then *(x) = sign(f̃ (x)). Furthermore, for any f,
The proof of Theorem 1 follows from Proposition 3.1 and Theorem 3.2 in [26] by treating V 
as the treatment assignment in their context, and thus omitted here.
Our next two theorems provide convergence rates for ℛ(f̂) − ℛ(f*), where f̂ is the estimated 
decision function by minimizing (5) for the paired design and (8) for the unpaired design 
when ℒ(z) = (1 − z)+ and ℋ is chosen to be the RKHS associated with the Gaussian kernel 
with bandwidth 1/σn. The particular choice of ℋ is due to the fact that any L2-integral 
function can be well approximated by the function in ℋ if σn is chosen to be large enough 
[25]. To state the convergence rate, we need the so-called geometric noise assumption for the 
probability distribution (W, V, X), which assumes that there exists a constant C > 0 such that
where q is a constant in (0, ∞), d is the dimension of X, and Δ(x) is the distance of x to the 
region {x′ : f(x)f(x′) < 0}. This condition is used in [25] to derive the convergence property 
for the support vector machine. Some examples of q are given in [25]. Our next Theorem 2 
gives the asymptotic property of f̂ for the paired design.
Theorem 2
In a paired design, let f̂ minimize (5) in ℋ. Suppose . Then for any δ > 0, 0 < 
ν < 2, there exists a constant c(ν, δ, d) such that
where  with c1 = 2/(2 + ν) + (2 − 
ν)(1 + δ)/[(2 + ν)(1 + q)]. Furthermore, if we choose λn = n−c2 where c2 = 2(1+q)/([(4 + 
ν)q + 2 + (2 − ν)(1 + δ)], then ℛ(f̂n) − R* = Op(n−c2q/(1+q)).
Theorem 2 shows that with proper choice of the bandwidth for the Gaussian kernel for ℋ, 
the convergence rate of the risk for f̂n, as compared to the Bayes risk, is of a polynomial 
order in n. The proof Theorem 2 follows exactly the same arguments as proving Theorem 
3.4 in [26], where their R is equivalent to our W and their A is equivalent to our V. Thus we 
skip the proof.
We now consider the unpaired design. We note the difference between (8) and (5) is the 
kernel approximation
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Then f̂, which minimizes (8), minimizes
where Pn denotes the empirical measure. Thus, to establish the convergence rate of ℛ(f̂), it 
is necessary to examine the approximation of ĝ(O, M; f) to Wℒ(V f) which depends on the 
kernel approximation using kan (·). This gives the following theorem.
Theorem 3
Under the same conditions in Theorem 2 and the same choices of λn and σn, if we further 
assume the conditional density of X given (M, D, Y ) is twice-continuously differentiable 
and  with k(·) being a kernel function symmetric with respect to 0, 
furthermore, supO |p̂(M, X, D) − p(M, X, D)| = Op(n−γ) for some γ > 0 and inf(M, X, D) p(M, 
X, D) > 0, then it holds
where c2 is a constant depending on (q, ν, δ).
The condition regarding p̂(M, X, D) in Theorem 3 concerns with the accuracy in estimating 
the propensity score. Particularly, if a parametric model is used to estimate p(M, X, D) 
consistently, it is clear γ = 1/2. Proof of Theorem 3 is provided in the Web Appendix A.
4. Numeric Studies
4.1. Simulations Under Paired Design
In a paired design, we observe both modalities A and B for all the subjects. We simulate a 
sample size of 100 subjects (n = 100), half of the subjects are diseased (Di = 1) and the other 
half are non-diseased (Di = 0). For each subject i with disease status Di = d, we generate Xi 
= (X1i, …, Xpi) from a uniform distribution on [0, 1]. We generate underlying continuous 
rating scores for modality A and B as
where (εAi, εBi) follows a bivariate normal distribution with mean zero, and we consider two 
cases for the covariance matrix of error terms for ỸA and ỸB: (1) independent case where 
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 so that assumption C.1 holds; and (2) correlated case where 
 as a sensitivity analysis. Next, to imitate real studies we obtain observed 
discrete rating scores as
Then we apply the proposed methods to determine the optimal personalized diagnostic rules.
We compare a few methods of modality assignment in terms of their ROC curves and AUC. 
The first two are “one-size-fits-all” rules where all subjects receive modality A or all 
subjects receive modality B. The next one is to estimate the optimal personalized rule 
depending on a subject’s covariates X without weighting by the magnitude of the difference 
of the rating scores on A and B,
The last method is to estimate the optimal personalized rule accounting for the magnitude of 
the difference of the rating scores:
We compare ROCs and AUCs produced by different methods based on 100 replications. In 
all simulation settings, we used an independent testing data set of 10, 000 samples to 
compute ROCs and AUCs. Specifically, for each cut point on the grid of (1, 2, 3, 4, 5, 6), we 
computed sensitivity and specificity of the estimated optimal modality and obtained the 
ROC and AUC. The tuning parameter Cn was chosen by cross validation across grid points 
of 2−15, 2−14, …, 214, 215.
In Table 1 and Figure 1, we report the results comparing diagnostic performance of four 
methods: (a) all receives modality A; (b) all receives modality B; (c) each subject receives 
modality chosen by wSVM1; and (d) each subject receives modality chosen by wSVM2. 
Table 1 summarizes the empirical AUCs and standard deviations across 100 replications of 
analyses (a) through (d) under several choices of ω and Figure 1 shows the average ROC 
curve. The proposed personalized diagnostic rule method performs similarly regardless of 
whether condition (C.1) holds or not (independent rating scores or correlated scores). When 
ω = 0.5 and 0.75, wSVM1 and wSVM2 increased the empirical AUC by about 5%. 
Although the average ROC curve of modality A and B are quite close, using ω = 0.5 or 0.75, 
the proposed optimal personalized rule assigning modality according to subject-specific 
covariates improves sensitivity and specificity at all thresholds compared to assigning all 
subjects to either A or B. Comparing wSVM1 and wSVM2, they have similar performance 
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except for ω = 0.25. In practice, the choice of ω depends on the relative importance of 
sensitivity and specificity in the target population where the diagnostic tool will be used. If 
no such prior information is available, a common choice is ω = 0.5.
Additional simulation results of unpaired design are provided in the Web Appendix B, where 
the results are similar to the paired design. We also provide a sensitivity analysis of violation 
of MAR for the unpaired analysis in Appendix D.
4.2. Simulation 2: a Breast Cancer Study
In this setting, we imitate a breast cancer screening study with paired modality measures [3], 
where we compare mammography with the combined screening using both mammography 
and MRI. Several covariates are considered: X1 is a subject’s age where older age is 
associated with a greater risk for breast cancer; X2 is BRCA1 or BRCA2 mutation status 
where carriers of either mutation will have a greater risk; X3 is the density of breast where it 
is more difficult for mammography alone to detect tumor for denser breasts. Age, mutation 
status and breast density are observed subject-specific covariates. In our simulation settings, 
we simulate MRI to be more sensitive to detect smaller tumor, and mammography to have 
the same sensitivity but higher specificity for larger tumor. To be more realistic, we also 
simulated tumor size (X4) as an additional unobserved variable to be associated with breast 
cancer risk but not available at the screening stage without biopsy, and we assumed X4 to be 
increasing with age. In this simulation scenario, all covariates X1 through X4 influence a 
radiologist’s ability to rate a tumor sample. Detailed simulation scheme and empirical AUC 
are provided in the Web Appendix C.
We compare ROCs and AUCs produced by different methods on an independent test set of 
10, 000 subjects and repeated simulations 100 times similar to the previous setting. 
Sensitivity, specificity and classification accuracy are presented in Table 2. Using 
mammography alone on all subjects leads to a lower sensitivity (84.2%) and higher 
specificity (99.5%), and combining mammography and MRI increases the sensitivity to 
99.6% with a reduced specificity of 89.7%. The personalized assignment of modality (either 
mammography alone or combined) using our proposed method wSVM1 and wSVM2 
increases the sensitivity to be close to modality B (98.5%) without sacrificing the specificity 
(94.1% and 94.2%). Thus, wSVM1 and wSVM2 reduce the overall miss-classification rate 
from 8.30% for mammography alone and 5.24% for mammography and MRI combined to 
3.64% and 3.61%, respectively.
To demonstrate the interpretability of our proposed method, the linear rule estimated in one 
replication is f(X) = 1.21 − 0.47 X1 − 0.38 X2 − 0.97 X3 for wSVM1 and f(X) = 1.23 − 0.43 
X1 − 0.33 X2 − 0.98 X3 for wSVM2. The fitted rule recommends the more sensitive 
combined test of MRI and mammography to older subjects with the BRCA1 or BRCA2 
mutation due to their higher risk of breast cancer. The negative coefficient for X3 suggests 
subjects with denser breast tissues are more likely to benefit from the combined test since 
the tumors may be harder to be detected using mammography alone. In contrast, for younger 
subjects without the BRCA mutations and with thinner breast tissues, using mammography 
alone may be optimal.
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5. Real Data Example: a Parkinson’s Disease Study
In this section, we analyze data collected from a Parkinson’s disease (PD) imaging study 
[27]. PD is a disabling neurodegenerative disorder diagnosed on the basis of cardinal motor 
features, including asymmetric bradykinesia, rigidity, and tremor [28]. In addition to motor 
impairment, clinically important non-motor symptoms such as anxiety, depression, apathy, 
and cognitive dysfunction frequently occur and have a major impact on quality of life [29]. 
Recent research on PD diagnosis is shifting from relying on clinical symptoms to predicting 
PD at risk status before onset of clinical symptoms using biomarkers [30]. There has been 
considerable interest in evaluating the potential of advanced non-invasive neuroimaging 
techniques, such as positron emission computed tomography (PET), and magnetic resonance 
imaging (MRI) to provide objective measures of dysfunction in PD, thereby enabling 
accurate diagnosis, predicting disease onset, and monitoring disease progression [9]. 
Previous study revealed a specific metabolic pattern that was associated with the diagnosis 
of PD from [18F]-fluorodeoxyglucose (FDG)-PET images, which involved significant 
elevated brain metabolism in bilateral posterior lentiform nucleus and posterior cingulate, 
and metabolic reductions in bilateral temporo-parietal association cortex in PD as compared 
to matched controls [27]. In addition, diffusion tensor imaging (DTI) MRI showed 
significantly increased mean diffusivity (MD) values in the posterior cingulate and 
decreased fractional anisotropy (FA) values in the white matter, which were both associated 
with memory deficits in PD, as assessed by California Verbal Learning Test.
Given the heterogeneous nature of PD and the fact that the course of disease progression 
varies among different individuals, it is important to develop methods for personalized 
recommendation to assist diagnosis of PD based on individual risk factors. Our proposed 
methods are used to explore whether there are subgroups of PD patients whose measures 
from FDG-PET might be a better screening marker compared with DTI. Imaging 
examinations and neuropsychological assessments for each participant were completed 
within a one-month time period. Imaging of PD subjects was performed in the practically-
defined off state, after antiparkinsonian medications had been withheld for 12 hours. 
Subjects with PD underwent a full Unified Parkinsons Disease Rating Scale (UPDRS) [31] 
examination performed by a neurologist. Mood and behavior were measured in terms of 
depressive symptoms with the Beck Depression Inventory-II [32]. The diagnosis of PD was 
made according to United Kingdom Brain Bank criteria [33].
In our analysis, subject-specific covariates being considered include BDI score for 
depression, BAI score for anxiety, UPDRS motor symptoms categorized at 50%th, 75%th 
and 90%th quartiles, and demographic variables such as age, gender, and years of education. 
All feature variables were standardized before applying the proposed methods. One 
requirement for applying wSVM is that YA and YB are on the same scale and thus 
comparable. In the PD study, the imaging measures may not be on the same scale. Thus, we 
considered a rank-based measure by using percentiles obtained from the empirical 
distribution functions for each subject as YA and YB. Similar procedure is used in [34] to 
compare biomarkers measured on the different scales. Our analysis sample includes both 
paired and unpaired data. There are 32 patients (19 cases and 13 controls) on whom both 
image modalities were measured and with no missing data on the feature variables. There 
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are 34 subjects who have only one modality, where 16 subjects (7 cases) have only MRI 
measures, and 18 subjects (11 cases) have only PET measures. To compare different 
methods, we used “leave-one-out” cross validation to compute AUC: for each subject, we 
used all other subjects as the training data set, and predicted the optimal modality for this 
subject; we then pooled all these “validation” data to calculate the AUCs using those 
subjects whose actual modalities were the same as the optimal modalities.
We first show the results for paired data. We compare fractional anisotropy (FA) in white 
matter and metabolic rate in the parietal lope (PAR). For two one-size-fits-all rules, the 
empirical AUC is 89.9% if using FA as a PD diagnostic measure on all subjects and 71.7% if 
using PAR, indicating FA is preferable. To fit a personalized diagnostic rule, we examine 
both weighted and unweighted schemes. Considering all 7 aforementioned covariates, 
wSVM2 chooses FA as the better screening modality for all subjects and gives the empirical 
AUC of 89.9%, while wSVM1 choose FA for all but 2 subjects, and gives an empirical AUC 
of 88.1%. If excluding UPDRS, both wSVM schemes will choose the superior screening 
method, FA, for all subjects. The ROC curves are shown in Figure 2a. In terms of the fitted 
diagnostic function, the intercepts for wSVM1 is 0.29, and 0.22 for wSVM2, and the 
coefficients for the feature variables are negligible (on the scale of 10−5), indicating none of 
the feature variables distinguishes the diagnostic ability between FA and PAR, and thus there 
is no clear subgroup for which one modality outperforms the other. In this paired data 
analysis, we demonstrated that when there is a universally superior modality (in this case, 
FA) and no subgroup for which the alternative modality improves performance can be found, 
the proposed method will choose the modality with superior performance.
Next, we show results of unpaired analysis. Here we compare the mean diffusivity (MD) 
measure in the posterior cingulate obtained from DTI-MRI and metabolic rate in the 
lentiform nucleus obtained from FDG-PET. The empirical AUC is presented in Figure 2b. 
Comparing two one-size-fits-all rules, MD at posterior cingulate on the unpaired sample has 
an AUC= 87.3% and the metabolic rate at the lentiform nucleus has an AUC= 57.1%. The 
same feature variables as the paired data analysis are used to fit personalized diagnostic 
rules. Here, we used a triangular kernel where , the tuning 
parameter of bandwidth was chosen to be an = 3 so that there were 90 pairs with none zero 
kernel weights (i.e., 31% of total number of pairs). We see that wSVM1 estimated a 
diagnostic rule with a higher AUC than using MD alone (93.7% compared to 87.3%), and 
wSVM2 achieved an AUC of 85.71%.
The coefficients of the fitted diagnostic rule are presented in Table 3. MD was measured in 
the posterior cingulate area located at the cingulate cortex. This area is related to emotion 
and memory. Subjects with higher anxiety score (adjusting for other covariates) may be 
potentially associated with higher deterioration in posterior cingulate area. Thus, MD 
measured in this area might be a more sensitive measure for PD patients showing more 
emotional symptoms (e.g., higher anxiety score). Deterioration in lentiform nucleus is 
related to motor impairment. For PD patients with more motor symptoms (e.g., with higher 
UPDRS percentile score) and less anxiety symptoms, metabolic rate at the lentiform nucleus 
may be a more sensitive measure. In this analysis, we demonstrated that examining 
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personalized diagnostic rules has the potential to identify subgroups suitable for applying 
different diagnostic measures, and provides insights on effectiveness of alternative 
modalities for clinical researchers. Due to the small sample size and exploratory feature of 
the analyses, a larger study is needed to confirm our findings.
6. Discussion
In this work, we proposed a data-driven approach to estimate optimal personalized 
diagnostic rule that may depend on subject-specific characteristics such as individual risk 
factors, biomarkers or subject preference. By drawing a connection with machine learning 
techniques, the approach can easily handle high-dimensional biomarkers and enjoys 
robustness of nonparametric decision rules and flexible nonlinear boundaries. The fitted 
diagnostic rule maximizes a weighted sum of sensitivity and specificity with a user-specified 
weight. Our theoretical studies examine convergence rate of the fitted decision rule to the 
true optimal rule. Simulation studies and real data example demonstrate superior 
performance of the individualized rules in some cases compared to the “one-size-fits-all” 
rules where all subjects receive the same modality.
As a note, a similar outcome weighted learning approach has been used in [26] to estimate 
the best individualized treatment rule among two treatment options according to patient-
specific features. Although both papers use weighted SVM for computation, the key 
difference between this paper and [26] is that our method focuses on selecting personalized 
rules to optimize diagnostic performance measures, while [26] aims for maximizing reward 
outcome. Thus, our objective function relates to sensitivity and specificity and depends on 
direct comparisons of potential outcomes, but this is not the case in [26] which focuses on 
marginal mean of either potential outcome. Furthermore, data for our analysis can come 
from very different designs such paired and unpaired as well as multiple readers; but [26] 
focuses on a single-stage randomized trial design.
In this work, we proposed using the kernel method to approximate the optimization 
objective (3) for the unpaired design. It relies on the kernel function to measure the 
closeness of each pairs. There are situations where the kernel method encounters difficulties: 
(1) when the dimension of covariates is high; (2) when the types of covariates are mixtures; 
(3) when the covariates have missing entries. When the dimension of covariate space is high, 
samples are sparsely distributed in the space, and each sample may not be close to any of its 
neighbors. Solutions to be considered include using dimension reduction techniques via 
nonparametric methods (e.g., PCA, slice inverse regression) or semiparametric/parametric 
models of the performance scores given the covariates (e.g., linear models, single index 
models), so that a reduced dimensional set of covariates will be included in our approach. 
Furthermore, variable selection techniques can be incorporated in these procedures to 
remove non-informative covariates. Challenges also arise when the covariates contain 
various types (continuous, categorical, binary), one can combine multiple types of distance 
(e.g., Euclidean distance for continuous covariates, Hamming distance for categorical 
variables) in the kernel matrix. Lastly, when there are missing values in the covariates, 
multiple imputation can be used before computing the kernel weights. For the step of 
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implementing the SVM classifier, one can adopt some imputation based SVM ([21], page 
333) to handle the missingness using modified risk function [35].
Our approach here considers maximizing diagnostic performance of a clinical test at the 
diagnostic stage, which is the first step of the clinical care continuum [36]. When 
information at other stages are available (i.e., treatment received) and maximizing long term 
morbidity or minimizing mortality is the ultimate goal, it is conceivable that a multiple stage 
decision rule which dynamically determines diagnostic choice and treatment choice can be 
constructed. Our method can be extended to handle multi-stage personalized rules by a 
backward induction procedure similar to that used for estimating optimal multi-stage 
personalized treatment rules [37]. Another interesting extension may be to consider 
comparing two screening strategies with different timing or frequency, and thus extends the 
current optimization method from choosing between two modalities to choosing on a 
continuous scale (timing of screening). Lastly, the proposed methods are illustrated through 
retrospective case-control diagnostic studies. For prospectively studies, it may be more 
appropriate to assess positive predictive values (PPV) and negative predictive values (NPV). 
An extension towards this direction would also be of interest.
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Appendix A. Proof of Theorem 3
First, from the fact
we have
By the uniform convergence of kernel approximation (c.f., [38]), 
. Therefore, we obtain a preliminary upper bound 
of
which is also an upper bound for the L∞-norm of f̂ by the embedding property of ℋ.
Next, the same proof as Theorem 1 gives
where q(X) is the marginal density of X. Then using the fact that f̂ minimizes (8), we have
Thus, it gives
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For the first term in (A.1), we note that ĝ(O,M; f) is Lipschitz continuous in f and according 
Theorem 2.1 in [25], the entropy for the unit ball of ℋ is of order . 
Therefore, using the large deviation results for the empirical process (Theorem 2.14.10, 
[39]), we conclude that this term is
For the last two terms in (A.1), we again apply the uniform approximation property to 
ĝ(O,M; f̂) plus the approximation p̂(M,X,D) to obtain




Combining these results, we obtain
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Theorem 3 thus holds from the choice of λn and σn in Theorem 2.
Appendix B. Simulations Under the Unpaired Design
We simulated covariates Xi, disease status Di and screening scores YAi and YBi under a 
similar procedure as the paired design in section 4.1. In addition, we created random 
variable M = 1when modality A is observed and M = −1 when modality B is observed. We 
implemented the unpaired algorithm with a triangular kernel . We 
simulated three scenarios where the modalities were generated following equation 1 and 2. 
Case 1 and 2 has p = 6 dichotomized variables Xi’s. Here we considered equal weights ω = 
0.5. The kernel bandwidth tuning parameter an were chosen to be 1.5 for the binary cases so 
the the number of pairs with strictly positive weights were around 350 when the sample size 
is 64, and 1400 when the sample size is 128, which is approximately 30% of the total pairs. 
Simulation case 3 of the unpaired design considered the same modalities with continuous 
covariates, where X was generated from a multivariate normal distribution with p = 10. The 
sample size was n = 100. We considered the same two scenarios for the covariance matrix of 
error terms for YA and YB, ω = 0.5. The kernel bandwidth tuning parameter an was set to be 
1, and there were approximately 350 pairs with non-zero kernel, approximately 15%.
The results are reported in Table B1 and Figure B1. The methods perform similarly for 
independent modality measurements and correlated modality measurements. Comparing 
case 1 and 2, we see that the increase of sample size from 6 to 128 greatly improves the 
performance of the proposed method. In these settings, wSVM2 performs better than 
wSVM1. For example, in case 2, it improves the empirical AUC by 13%, and we see a large 
gap between its average ROC curve compared to other three methods. Thus weighting by the 
magnitude of the difference in two modality screening scores makes a difference in this 
simulation scenario. Case 3 is a more difficult case, where there are more noise variables, 
and the covariates are continuous instead of categorical. Our proposed methods wSVM1 and 
wSVM2 both improve the empirical AUC over “one-size-fits-all” rules by approximately 
1% and 4%, respectively.
Table B1
Mean (SD) for Empirical AUC for Unpaired Design Simulation with independent and 
correlated modality measurements
modality A modality B wSVM1 wSVM2
Independent Correlated Independent Correlated
Case 1 0.739 0.752 0.751(0.026) 0.753(0.027) 0.771(0.05) 0.767(0.047)
Case 2 0.739 0.752 0.765(0.053) 0.761(0.039) 0.834(0.083) 0.838(0.083)
Case 3 0.742 0.745 0.748(0.017) 0.750(0.021) 0.767(0.037) 0.775(0.039)
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Empirical ROC for Unpaired Design Simulation with independent and correlated modality 
measurements
Appendix C. Details of the Simulation Imitating a Breast Cancer Study in 
Section 4.2
Age X1 was simulated from a folded standard normal distribution which is the absolute 
value of a random variable following standard normal distribution, and BRCA gene type X2 
was generated from Bernoulli(0.1). The indicator for disease outcome D was generated from 
from a logistic model with logit(Pr(D = 1|X) = X1 + X2 − 0.8. For simplicity, we assume the 
screening outcome of mammography and MRI to be binary indicators of whether 
abnormality is detected, which is followed by a decision of whether biopsy should be 
referred. Modality A represents mammography alone, where YA = 1 denotes the detection of 
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abnormality under this modality. There were two variables influencing YA are X3 and X4, 
where density of breast X3 was simulated from a folded normal distribution, and tumor size 
(X4) was simulated by X4 = 0.3X1 + 0.7e1, with e1 simulated from a folded standard normal 
distribution. The binary outcome representing detection of abnormality was simulated from
where p is 0.01 + 0.98D − 0.4I(X4 < 0.1)D − 0.4I(X3 > 0.9)D) truncated by [0, 1]. Modality 
B represents combined mammography and MRI, where YB = 1 represents either 
mammography or MRI test detects abnormality, and
The box plot of empirical AUCs of the two proposed methods are presented in Figure C1. 
We observe a substantial increase in empirical AUC.
Figure C1. 
Empirical AUC for Breast Cancer based on n = 1000 and 100 replication
Table D1
Mean and SD of AUC of sensitivity analysis for unpaired modalities
Setting α modality A modality B wSVM1 wSVM2
1 0.5 0.739 0.752 0.749(0.024) 0.775(0.055)
1 1 0.739 0.752 0.751(0.026) 0.767(0.046)
2 0.5 0.739 0.752 0.749(0.022) 0.764(0.044)
2 1 0.739 0.752 0.746(0.028) 0.751(0.029)
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Appendix D. Sensitivity Analysis for the Unpaired Design in Simulation 
Studies
For the unpaired data we assumed missing at random (MAR), i.e., the choice of modality is 
independent of the measurement of modality given the observed feature covariates. Here we 
conducted sensitivity analysis for one simulation setting of unpaired design when this 
assumption is violated.
We generated data from case 1 in Appendix B with independent covariates. The choice of 
observed modality was generated depending on the modality measurement from a logistic 
model. There are two setting of this logistic model, setting 1 is logit(P(M = A|YA, YB)) = 
αYA + αYB − 6α)); and setting 2 is logit(P(M = A|YA, YB)) = αYA − αYB). The model 
suggests that the modality assignment may depend on potentially unobserved YA or YB, 
since in an unpaired design only one modality will be measured. In both settings, we let α 
take two values, 0.5 and 1. There are 200 replications conducted for each setting and α 
combination, and the AUC was computed from an independent testing data set of 10, 000 
observations. Table D1 presented the mean and SD of the AUC. Our proposed method in 
three settings shows stable superior performance than one-size-fits-all method. Compared 
with the results of no violation of MAR in Table B1, where wSVM1 achieves an AUC of 
0.751(0.026) and wSVM2 achieves 0.771(0.05), setting 2 is more affected by the violation 
of MAR assumption when α is large, that is, when the parameters of modality A and B have 
different signs in the logistic model generating the modality assignment. In this setting, with 
different signs, the comparative location of center is affected by the violation of MAR. 
When α has the same sign in setting 1, the result are less affected by the violation of MAR, 
because the comparative means of two modalities are not shifted by the violation of MAR.
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Average ROC for Paired Design with independent and correlated modality measurements 
within patients
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ROC curve for brain imaging study for Parkinson’s Diseases
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Table 2
Sensitivity and specificity for the breast cancer study simulation
Sensitivity Specificity Mis. Rate†
mammography 0.842 0.995 8.30%
mammography+MRI 0.996 0.897 5.24%
wSVM1 0.985 0.941 3.64%
wSVM2 0.985 0.942 3.61%
†
: Missclassification rate
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